English / Deutsch
Welcome to the
GENEART AG Investor Relations Website
Corporate Portrait
(according to guidelines of the Open Market at the Frankfurt Stock Exchange)
GENEART AG share data
|
Share identification number (WKN): |
A0JJ4L |
|
ISIN (International Securities Identification Number): |
DE000A0JJ4L4 |
|
Stock Exchange Code Deutsche Börse (German Stock Exchange): |
G6A |
|
Listing: |
Open Market of Frankfurt Stock Exchange (Entry Standard) |
|
Number of outstanding shares |
4,487,800 |
|
Capital Stock: |
4,487,800.00 € |
|
Shareholder Structure (key date 5/28/2010) |
Applied Biosystems Deutschland GmbH (German Subsidiary of Life Technologies Corporation): > 95% |
|
Lead Broker: |
Baader Bank AG |
|
Applicant: |
WestLB |
|
Designated Sponsor: |
WestLB |
|
German Stock Exchange Listing Partner: |
WestLB |
|
Date of IPO: |
May 23, 2006 |
View the GENEART AG stock chart
*provided by Deutsche Börse AG
(note: Your are leaving the GENEART AG web site and you are connected to
the Deutsche Börse AG web site)
Corporate Information
|
Date of Foundation: |
GENEART AG was founded on February 21, 2006 and entered in the Commercial Register on March 20, 2006.
The predecessor company GENEART GmbH was founded on November 5, 1999 and entered in the Commercial Register on December 7, 1999.
|
|
Accounting Standard: |
HGB (AG)/IFRS (Group) |
|
Fiscal Year-End: |
December, 31 |
|
Names and Functions of the Management Board and Supervisory Board Members: |
Management Board |
|
Prof. Dr. Ralf Wagner, CEO, CSO |
|
|
Dr. Marcus Graf, COO |
|
|
Bernd Merkl, CBO |
|
|
Daniel Seibert, CFO |
|
|
Supervisory Board |
|
|
Dr. Dieter Daniels |
|
|
Genoffir MacLeod |
|
|
Nathan Wood |
Business Description at a glance
GENEART AG is in the DNA engineering and processing business since 2000. “DNA engineering and processing” stands for developments and services that allow gene sequences to be selectively manipulated, redesigned, and reassembled according to rational requirements, and to be produced in larger quantities for various applications, including drug development. GENEART’s services portfolio ranges from the production of optimized synthetic genes, the generation of gene variants and gene libraries to the production of DNA-based active agents.
GENEART’s core business is gene synthesis (Custom Gene Synthesis & Services). In addition, GENEART also offers other services that are closely related to gene synthesis. These services cater to the ever-growing need for rationally designed gene variants and customized gene libraries, which are delivered preferentially in the customer-preferred plasmid vectors. The corresponding services are combined within the business areas of Directed Evolution and Plasmid Services. In addition GENEART offers products from the area of proteins and cell lines (Cell Lines & Proteins).
By using synthetic genes, gene variants as well as gene libraries, the development and production of modern drugs and bioproducts can be significantly improved and accelerated. Meanwhile, GENEART’s designed and produced genes are used by numerous pharmaceutical and chemical companies, biotechnology companies, as well as various universities and large research institutions to develop and manufacture new therapeutics and vaccines as well as to identify and produce improved industrial enzymes.
Print